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Background:  The novel oral anticoagulants may offer a significant improvement over warfarin. The aim of our study is to assess cost implications 
of substituting dabigatran for warfarin among patients with atrial fibrillation (AF) and venous thromboembolism (VTE) enrolled in a large 
anticoagulation management service (AMS). 
Methods:  The study population was identified using inclusion and exclusion criteria from the RE-LY and RE-COVER trials. We obtained labor costs 
($483 per patient) from the AMS budget, laboratory costs of International Normalized Ratio (INR) blood tests ($267 per patient), and Canadian 
retail prices in U.S. dollars of warfarin 5 mg tablets ($113 per patient) and dabigatran 110 mg capsules ($4246 per patient). 
Results:  A total of 1,774 (93.5%) patients were eligible based on trial criteria. The annual projected cost for anticoagulation with dabigatran is 
$7,532,404 for drug cost alone. The annual projected cost of warfarin management for the 1,774 dabigatran eligible patients is $1,530,962. This is 
comprised of $856,842 for labor, $473,658 for INR testing, and $200,462 for cost of warfarin. 
Conclusion: The vast majority of patients with AF and VTE in a large AMS are eligible for substitution of dabigatran 
for warfarin. Substitution will result in substantially increased expense. However, our analysis does not account for the 
potential decreased rate of bleeding and decreased risk of stroke observed in dabigatran treated patients in clinical trials. 
